Characteristic | N (%) |
---|---|
Sex | Â |
 Male | 16 (72.7%) |
 Female | 6 (27.3%) |
 Age | Median 50 (range 19–81) |
Primary site | Â |
 Oral cavity | 1 (4.5%) |
 Oropharynx | 6 (27.3%) |
 Nasopharynx | 7 (31.8%) |
 Larynx | 8 (36.4%) |
T stage | Â |
 T1 | 3 (13.6%) |
 T2 | 6 (27.2%) |
 T3 | 11 (50.0%) |
 T4 | 2 (9.1%) |
N stage | Â |
 N0 | 9 (40.9%) |
 N1 | 3 (13.6%) |
 N2 | 8 (36.3%) |
 N3 | 2 (9.1%) |
Group stage | Â |
 Stage I | 2 (9.1%) |
 Stage II | 5 (22.7%) |
 Stage III | 8 (36.4%) |
 Stage IV | 7 (31.8%) |
Treatment | Â |
 Chemoradiotherapy | 21 (95.5%) |
 Radiation alone | 1 (4.5%) |